Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary CryptoMapTM platform.
All the latest company news, press releases and updates from Epitopea.
We Are Epitopea

Revealing Novel Targets For Next Generation Immunotherapies

We believe better cancer therapies are needed to transform people’s lives. We are developing accessible off-the-shelf cancer RNA immunotherapies that will deliver durable benefits.

We Are Epitopea

Better cancer therapies are needed to transform patient responses and their lives. We are developing accessible off-the-shelf cancer RNA immunotherapies that we believe will deliver more durable benefits to patients.
Learn more
We are a global leader in exploiting a novel class of untapped, aberrantly expressed tumour-specific antigens (aeTSAs) or CryptigenTM TSAs that are shared across multiple patients with the same tumor type, for the development of off-the-shelf cancer vaccines across the landscape of difficult to treat cancers.
Epitopea is a transatlantic cancer immunotherapeutics company based in Montreal, Canada and Cambridge, UK.

Our proprietary CryptoMapTM platform, created and optimized by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer, at the Université de Montréal, identifies shared, aberrantly expressed tumour-specific antigens (aeTSAs), known as CryptigenTM TSAs, that are hidden in ‘junk DNA’.

Latest News

Scientist Live

Date: November 12, 2026 |
Epitopea announces first patient dosed in clinical trial of CryptiVaxTM-1001 Epitopea, a clinical-stage biotech company developing off-the-shelf, durable RNA-based cancer […]
Read More

BiotechTV

Date: November 11, 2026 |
BIO-Europe 2026: Epitopea has just started dosing patients in the first clinical trial of its RNA-based cancer vaccine CEO Alan […]
Read More

Femtech World

Date: November 10, 2026 |
Epitopea doses first patient in UK ovarian cancer vaccine trial The first patient has received an experimental ovarian cancer vaccine […]
Read More
Revealing Novel Targets For Next Generation Immunotherapies
© 2022 – 2026 Epitopea Ltd | All Rights Reserved
Created by FDM Digital